PHILADELPHIA, July 11, 2016 — Iroko Pharmaceuticals, LLC announced today the appointment of Louis J. Vollmer as President and Chief Executive Officer effective July 6, 2016. Mr. Vollmer has been serving as President of Iroko since March 2015 and continues as a member of Iroko’s Board of Directors, which he joined in February 2014. He succeeds Osagie Imasogie, Iroko’s Founder, as CEO; Mr. Imasogie will remain Iroko’s Chairman.
Mr. Vollmer will oversee the day-to-day operations and long term strategic planning of Iroko, focusing on maximizing the potential of Iroko’s SoluMatrix® franchise brands, expanding the company’s global presence and creating and acquiring innovative treatment options for responsible pain management.
“Lou is a seasoned and well respected leader whose perspective and business acumen will be invaluable to Iroko as it evolves into a true leader in providing responsible pain management options to healthcare professionals and patients,” said Mr. Imasogie.
Mr. Vollmer has over 25 years of experience in the pharmaceutical industry. He began his career at DuPont Merck, progressing quickly in roles of increasing responsibility and ultimately serving as Vice President of Sales & Marketing for DuPont Multi Source Products, with responsibility for more than 12 branded products. He then played a key role as one of three founding partners and management team leaders of Endo Pharmaceuticals, now a multi-billion dollar publicly traded company.
“I am honored to lead Iroko at this stage of the company’s evolution,” said Mr. Vollmer. “Iroko is in a strong position for growth within the United States and worldwide. I look forward to helping the company deliver significant value to patients and healthcare professionals and achieving strong and sustainable growth.”
About Iroko Pharmaceuticals, LLC
Iroko is a global specialty pharmaceutical company dedicated to scientific innovation in responsible pain management. Based in Philadelphia, the company develops and globally commercializes pharmaceutical products that significantly improve patient lives. By using breakthrough, proprietary technologies, strategic acquisition and the extensive expertise of our employees and specialist partners, Iroko continually delivers significant added value to patients, healthcare professionals and other stakeholders. For more information, visit www.iroko.com.
Caitlin Finnegan for Iroko Pharmaceuticals, LLC, 212-303-2321
Meg Kramer, Iroko Pharmaceuticals, LLC, 267-546-1656
SoluMatrix® is a trademark of iCeutica Pty Ltd and is licensed to Iroko.